Open Access<p>The Impact of Loading Dose on Outcome in Stroke Patients Receiving Low-Dose Tissue Plasminogen Activator Thrombolytic Therapy</p>
Author(s) -
YiSin Wong,
Sheng Feng Sung,
Chi-Shun Wu,
Yung-Chu Hsu,
YuHsiang Su,
Ling-Chien Hung,
Cheung-Ter Ong
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s235388
Subject(s) - medicine , tissue plasminogen activator , thrombolysis , bolus (digestion) , stroke (engine) , loading dose , t plasminogen activator , fibrinolytic agent , anesthesia , surgery , myocardial infarction , mechanical engineering , engineering
Intravenous tissue plasminogen activator (tPA) (0.9 mg/kg, maximum 90 mg) with a bolus of 10% of the total dose given within 1-2 mins is the standard therapy for patients receiving thrombolytic therapy. Low-dose (0.6 mg/kg) tPA is also approved for thrombolytic therapy for ischemic stroke patients. Low-dose tPA is associated with a low bolus dose. It is unknown whether increasing the bolus dose in patients receiving low-dose tPA thrombolysis may improve outcomes or increase the risk of hemorrhagic transformation (HT).